1. PS1 - 170 Bmi1 is a Therapeutic Target in Recurrent Childhood Medulloblastoma. (18th October 2016) Authors: Garg, N.; Bakhshinyan, D.; Manoranjan, B.; Venugopal, C.; Hallett, R.; Mahendram, S.; Vijayakumar, T.; Subapanditha, M.; Qazi, M.; Singh, M.; McFarlane, N.; Mann, A.; Vora, P.; Davis, T.; Singh, S. Journal: Canadian journal of neurological sciences Issue: Volume 43(2016)Supplement 4 Page Start: S10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PS2 - 171 Bmi1 Identifies Treatment-Refractory Stem Cells in Human Glioblastoma. (18th October 2016) Authors: Vora, P.; Qazi, M.; Venugopal, C.; Subapanditha, M.; Mahendram, S.; Chokshi, C.; Singh, M.; Bakhshinyan, D.; McFarlane, N.; Singh, S. Journal: Canadian journal of neurological sciences Issue: Volume 43(2016)Supplement 4 Page Start: S13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PS2 - 172 Preclinical Validation of a Novel CD33/CD3 Bispecific T-Cell Engager (BiTE) Antibody to Target Patient-Derived Glioblastoma Cells. (18th October 2016) Authors: Vora, P.; Venugopal, C.; Choksi, C.; Qazi, M.; Adams, J.; London, M.; Subapanditha, M.; Singh, M.; Bakshinyan, D.; Sidhu, S.; Moffat, J.; Singh, S. Journal: Canadian journal of neurological sciences Issue: Volume 43(2016)Supplement 4 Page Start: S13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗